Bortolus Renata, Blom Fenneke, Filippini Francesca, van Poppel Mireille N M, Leoncini Emanuele, de Smit Denhard J, Benetollo Pier Paolo, Cornel Martina C, de Walle Hermien E K, Mastroiacovo Pierpaolo
Office for Research Promotion, Department of the Hospital Management and Pharmacy, Verona University Hospital, P,le A, Stefani, 1-37126 Verona, Italy.
BMC Pregnancy Childbirth. 2014 May 13;14:166. doi: 10.1186/1471-2393-14-166.
In 2010 a Cochrane review confirmed that folic acid (FA) supplementation prevents the first- and second-time occurrence of neural tube defects (NTDs). At present some evidence from observational studies supports the hypothesis that FA supplementation can reduce the risk of all congenital malformations (CMs) or the risk of a specific and selected group of them, namely cardiac defects and oral clefts. Furthermore, the effects on the prevention of prematurity, foetal growth retardation and pre-eclampsia are unclear.Although the most common recommendation is to take 0.4 mg/day, the problem of the most appropriate dose of FA is still open.The aim of this project is to assess the effect a higher dose of peri-conceptional FA supplementation on reducing the occurrence of all CMs. Other aims include the promotion of pre-conceptional counselling, comparing rates of selected CMs, miscarriage, pre-eclampsia, preterm birth, small for gestational age, abruptio placentae.
METHODS/DESIGN: This project is a joint effort by research groups in Italy and the Netherlands. Women of childbearing age, who intend to become pregnant within 12 months are eligible for the studies. Women are randomly assigned to receive 4 mg of FA (treatment in study) or 0.4 mg of FA (referent treatment) daily. Information on pregnancy outcomes are derived from women-and-physician information.We foresee to analyze the data considering all the adverse outcomes of pregnancy taken together in a global end point (e.g.: CMs, miscarriage, pre-eclampsia, preterm birth, small for gestational age). A total of about 1,000 pregnancies need to be evaluated to detect an absolute reduction of the frequency of 8%. Since the sample size needed for studying outcomes separately is large, this project also promotes an international prospective meta-analysis.
The rationale of these randomized clinical trials (RCTs) is the hypothesis that a higher intake of FA is related to a higher risk reduction of NTDs, other CMs and other adverse pregnancy outcomes. Our hope is that these trials will act as catalysers, and lead to other large RCTs studying the effects of this supplementation on CMs and other infant and maternal outcomes.
Italian trial: ClinicalTrials.gov Identifier: NCT01244347.Dutch trial: Dutch Trial Register ID: NTR3161.
2010年一项Cochrane综述证实,补充叶酸(FA)可预防神经管缺陷(NTDs)首次和再次发生。目前,一些观察性研究的证据支持这样的假设,即补充FA可降低所有先天性畸形(CMs)的风险,或降低其中特定一组先天性畸形(即心脏缺陷和唇腭裂)的风险。此外,其对预防早产、胎儿生长受限和先兆子痫的作用尚不清楚。尽管最常见的建议是每天服用0.4毫克,但FA最合适剂量的问题仍未解决。本项目的目的是评估更高剂量的孕前FA补充剂对降低所有CMs发生率的效果。其他目的包括促进孕前咨询、比较特定CMs、流产、先兆子痫、早产、小于胎龄儿、胎盘早剥的发生率。
方法/设计:本项目由意大利和荷兰的研究小组共同开展。打算在12个月内怀孕的育龄妇女符合研究条件。妇女被随机分配每天接受4毫克FA(研究中的治疗组)或0.4毫克FA(对照治疗组)。妊娠结局信息来自妇女和医生提供的信息。我们预计在一个总体终点(如:CMs、流产、先兆子痫、早产、小于胎龄儿)中综合考虑所有妊娠不良结局来分析数据。总共需要评估约1000例妊娠,以检测频率绝对降低8%。由于分别研究各个结局所需的样本量很大,本项目还推动了一项国际前瞻性荟萃分析。
这些随机临床试验(RCTs)的基本原理是这样的假设,即更高的FA摄入量与NTDs、其他CMs及其他不良妊娠结局的风险降低幅度更大有关。我们希望这些试验将起到催化剂的作用,并引发其他大型RCTs来研究这种补充剂对CMs及其他母婴结局的影响。
意大利试验:ClinicalTrials.gov标识符:NCT01244347。荷兰试验:荷兰试验注册编号:NTR3161。